Advertisement

Dysthyroidism and Chronic Heart Failure: Pathophysiological Mechanisms and Therapeutic Approaches

  • Caterina Rizzo
  • Margherita Ilaria Gioia
  • Giuseppe Parisi
  • Vincenzo Triggiani
  • Massimo IacovielloEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1067)

Abstract

Among comorbidity in chronic heart failure (CHF), dysthyroidism represents a relevant problem especially in the ageing CHF patients worldwide. Thyroid greatly affects many cardiovascular activities and its dysfunction may worsen a CHF condition. In particular, hypothyroidism has a relative high prevalence in patients with heart failure and it plays a key role in influencing CHF onset, progression and prognosis. Hyperthyroidism, is less frequent in this clinical context but it necessitates of immediate treatment because of its negative effects on cardiovascular balance. Also, it must be considered that dysthyroism may also be iatrogenic and the main responsible drug is Amiodarone.

Based on the best available evidence and our cumulative clinical experience, this manuscript analyzes the prevalence, the pathophysiology and the prognostic impact of thyroid disorders in chronic heart failure.

Keywords

Chronic heart failure hypothyroidism hyperthyroidism Amiodarone 

References

  1. Arcopinto M, Salzano A, Bossone E, Ferrara F, Bobbio E, Sirico D, Vriz O, De Vincentiis C, Matarazzo M, Saldamarco L, Saccà F, Napoli R, Iacoviello M, Triggiani V, Isidori AM, Vigorito C, Isgaard J, Cittadini A (2015a) Multiple hormone deficiencies in chronic heart failure. Int J Cardiol 184:421–423CrossRefPubMedGoogle Scholar
  2. Arcopinto M, Salzano A, Isgaard J, Cittadini A (2015b) Hormone replacement therapy in heart failure. Curr Opin Cardiol 30(3):277–284CrossRefPubMedGoogle Scholar
  3. Arcopinto M, Salzano A, Giallauria F, Bossone E, Isgaard J, Marra AM, Bobbio E, Vriz O, Åberg DN, Masarone D, De Paulis A, Saldamarco L, Vigorito C, Formisano P, Niola M, Perticone F, Bonaduce D, Saccà L, Colao A, Cittadini A, T.O.S.CA. (Trattamento Ormonale Scompenso CArdiaco) Investigators (2017) Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study. PLoS One 12(1):e0170058CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association and American Association of Clinical Endocrinologists (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17:456–520CrossRefPubMedGoogle Scholar
  5. Baker O, Van Beeren HC, Wiersinga WM (1994) Desetylamiodarone is a non-competitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta1-receptor protein. Endocrinology 134:1665–1670CrossRefGoogle Scholar
  6. Biondi D, Cooper DS (2008) The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29:76–131CrossRefPubMedGoogle Scholar
  7. Biondi B, Palmieri EA, Lombardi G, Fazio S (2002) Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 87:968–974CrossRefPubMedGoogle Scholar
  8. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G (2005) Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 152:1–9CrossRefPubMedGoogle Scholar
  9. Bogazzi F, Bartalena L, Brogioni S, Burelli A, Raggi F, Ultimieri F, Cosci C, Vitale M, Fenzi G, Martino E (2001) Desetylamiodarone antagonizes the effect of thyroid hormone at the molecular level. Eur J Endocrinol 145:59–64CrossRefPubMedGoogle Scholar
  10. Bogazzi F, Bartalena L, Cosci C et al (2003) Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 88:1999–2002CrossRefPubMedGoogle Scholar
  11. Brenta G, Danzi S, Klein I (2007) Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 3:632–640CrossRefPubMedGoogle Scholar
  12. Butler J, Kalogeropoulos A (2008) Worsening heart failure hospitalization epidemic: we do not know how to prevent and we do not know how to treat. J Am Coll Cardiol 52:435–437CrossRefPubMedGoogle Scholar
  13. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB (2008) Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 1:125–133CrossRefPubMedPubMedCentralGoogle Scholar
  14. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160:526–534CrossRefPubMedGoogle Scholar
  15. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW (2006) Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295:1033–1041CrossRefPubMedPubMedCentralGoogle Scholar
  16. Chen WJ, Lin KH, Lee YS (2000) Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha 1 collagen gene expression by thyroid hormone receptors. Mol Cell Endocrinol 162:45–55CrossRefPubMedGoogle Scholar
  17. Chen S, Shauer A, Zwas DR, Lotan C, Keren A, Gotsman I (2014) The effect of thyroid function on clinical outcome in patients with heart failure. Eur J Heart Fail 16(2):217–226CrossRefPubMedGoogle Scholar
  18. Chopra IJ (1997) Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 82:329–334CrossRefPubMedGoogle Scholar
  19. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Mueller B (2003) Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 166:379–386CrossRefPubMedGoogle Scholar
  20. Cooper DS (2001) Clinical practice. Subclinical hypothyroidism. N Engl J Med 345:260–265CrossRefPubMedGoogle Scholar
  21. Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379:1142–1154CrossRefPubMedGoogle Scholar
  22. Cruz FE, Cheriex EC, Smeets JL, Atie J, Peres AK, Penn OC, Brugada P, Wellens HJ (1990) Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 16:739–744CrossRefPubMedGoogle Scholar
  23. Dalström U (2005) Frequent non-cardiac comorbidities in patients with chronic heart failure. Eur J Heart Fail 7:309–316CrossRefGoogle Scholar
  24. De Pergola G, Nardecchia A, Giagulli VA, Triggiani V, Guastamacchia E, Minischetti MC, Silvestris F (2013) Obesity and heart failure. Endocr Metab Immune Disord Drug Targets 13(1):51–57CrossRefPubMedGoogle Scholar
  25. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC (2015) Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3(2):136–145CrossRefGoogle Scholar
  26. Dillman WH (1990) Biochemical basis of thyroid hormone action in the heart. Am J Med 88:626–630CrossRefGoogle Scholar
  27. Dillmann WH (2002) Cellular action of thyroid hormone on the heart. Thyroid 12:447–452CrossRefPubMedGoogle Scholar
  28. Fazio S, Palmieri EA, Lombardi G, Biondi B (2004) Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 59:31–50CrossRefPubMedGoogle Scholar
  29. Feldman T, Borow KM, Sarne DH, Neumann A, Lang RM (1986) Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contractile state. J Am Coll Cardiol 7:967–974CrossRefPubMedGoogle Scholar
  30. Fiore G, Suppressa P, Triggiani V, Resta F, Sabba C (2013) Neuroimmune activation in chronic heart failure. Endocr Metab Immune Disord Drug Targets 13(1):68–75CrossRefPubMedGoogle Scholar
  31. Fiore V, Marci M, Poggi A, Giagulli VA, Licchelli B, Iacoviello M, Guastamacchia E, De Pergola G, Triggiani V (2015) The association between diabetes and depression: a very disabling condition. Endocrine 48(1):14–24CrossRefPubMedGoogle Scholar
  32. Forfar JC, Muir AL, Sawers SA, Toft AD (1982) Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med 307:1165–1170CrossRefPubMedGoogle Scholar
  33. Franklyn JA, Green NK, Gammage MD, Alhquist JA, Sheppard MC (1989) Regulation of alpha- and beta-myosin heavy chain messenger RNAs in the rat myocardium by amiodarone and by thyroid status. Clin Sci (Lond) 76:463–467CrossRefGoogle Scholar
  34. Freedberg AS, Papp JG, Williams AM (1970) The effect of altered thyroid state on atrial intracellular potentials. J Physiol 207(2):357–369CrossRefPubMedPubMedCentralGoogle Scholar
  35. Frost L, Vestergaard P, Mosekilde L (2004) Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 164:1675–1678CrossRefPubMedGoogle Scholar
  36. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N (2012) Thyroid Studies Collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 126(9):1040–1049CrossRefPubMedGoogle Scholar
  37. Gerdes AM (2015) Restoration of thyroid hormone balance: a game changer in the treatment of heart failure? Am J Physiol Heart Circ Physiol 308:H1–H10CrossRefPubMedGoogle Scholar
  38. Giagulli VA, Guastamacchia E, De Pergola G, Iacoviello M, Triggiani V (2013a) Testosterone deficiency in male: a risk factor for heart failure. Endocr Metab Immune Disord Drug Targets 13(1):92–99CrossRefGoogle Scholar
  39. Giagulli VA, Moghetti P, Kaufman JM, Guastamacchia E, Iacoviello M, Triggiani V (2013b) Managing erectile dysfunction in heart failure. Endocr Metab Immune Disord Drug Targets 13(1):125–134CrossRefGoogle Scholar
  40. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RG (2004) Thyroid status, disability and cognitive function, and survival in old age. JAMA 292(21):2591–2599CrossRefPubMedGoogle Scholar
  41. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC (2000) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 132:270–278CrossRefPubMedGoogle Scholar
  42. Hamilton MA, Stevenson LW, Luu M, Walden JA (1990) Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16:91–95CrossRefPubMedGoogle Scholar
  43. Hayashi T, HasegawaT KH, Funada A, Amaki M, Takahama H, Ohara T, Sugano Y, Yasuda S, Ogawa H, Anzai T (2016) Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure. ESC Heart Failure 3:168–176CrossRefPubMedPubMedCentralGoogle Scholar
  44. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE (2002) Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab 87:489–499CrossRefPubMedGoogle Scholar
  45. Huber G, Staub JJ, Meier C, Mitrache C, Guglielmetti M, Huber P, Braverman LE (2002) Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Meatab 87:3221–3226CrossRefGoogle Scholar
  46. Iacoviello M, Guida P, Guastamacchia E, Triggiani V, Forleo C, Catanzaro R, Cicala M, Basile M, Sorrentino S, Favale S (2008) Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des 14:2686–2692CrossRefPubMedGoogle Scholar
  47. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L’Abbate A, Pingitore A (2007) Association between increase mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526–1532CrossRefPubMedGoogle Scholar
  48. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update: ACCF/AHA guidelines for the diagnosis and Management of Heart Failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:1977–2016CrossRefPubMedGoogle Scholar
  49. Kahaly GJ, Dillmann WH (2005) Thyroid hormone action in the heart. Endocr Rev 26:704–728CrossRefPubMedGoogle Scholar
  50. Kannan R, Ookhtens M, Chopra IJ, Singh BN (1984) Effects of chronic administration of amiodarone on kinetics of metabolism of iodothyronines. Endocrinology 115:1710–1716CrossRefPubMedGoogle Scholar
  51. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL (1994) The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 23:586–590CrossRefPubMedGoogle Scholar
  52. Klein I, Danzi S (2007) Thyroid disease and the heart. Circulation 116:1725–1735CrossRefPubMedGoogle Scholar
  53. Klein I, Ojamaa K (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344:501–509CrossRefPubMedGoogle Scholar
  54. Kozdag G, Ural D, Vural A, Agacdiken A, Kahraman G, Sahin T, Ural E, Komsuoglu B (2005) Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail 7:113–118CrossRefPubMedGoogle Scholar
  55. Levey GS, Klein I (1994) Disorders of the thyroid. In: Stein’s textbook of medicine, 2nd edn. Little Brown & Co, Boston, p 1383Google Scholar
  56. Loh KC (2000) Amiodarone-induced thyroid disorders: a clinical review. Postgrad Med J 76:133–140CrossRefPubMedPubMedCentralGoogle Scholar
  57. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR (1997) Changes in gene expression in the intact human heart. Downregulation of alpha- myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:2315–2324CrossRefPubMedPubMedCentralGoogle Scholar
  58. Manowitz NR, Major GH, Klepper MJ, DeGroot LJ (1996) Subclinical hypothyroidism and euthyroid sick syndrome in patients with moderate-to-severe congestive heart failure. Am J Ther 3:797–801CrossRefPubMedGoogle Scholar
  59. Martino E, Bartalena L, Bogazzi F, Braverman LE (2001) The effects of amiodarone on the thyroid. Endocr Rev 22(2):240–254PubMedGoogle Scholar
  60. Monzani F, Caraccio N, Kozàkowà M, Dardano A, Vittone F, Virdis A, Taddei S, Palombo C, Ferrannini E (2004) Effect of levothyroxine replacement on lipid profile and intima-media tickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 89:2099–2106CrossRefPubMedGoogle Scholar
  61. Mooijaart SM on behalf of the IEMO 80-Plus Thyroid Trial Collaboration (2014) Letter regarding the Paper by Pearce et al. Entitled ce European Journal of Endocrinology 2017], 25 mcg/day, with European Thyroid Journal 3:1414Google Scholar
  62. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA (1997) Myosin heavy chain gene expression in human heart failure. J Clin Invest 100:2362–2370CrossRefPubMedPubMedCentralGoogle Scholar
  63. Ning N, Gao D, Triggiani V, Iacoviello M, Mitchell JE, Ma R, Zhang Y, Kou H (2015) Prognostic role of hypothyroidism in heart failure: a meta-analysis. Medicine (Baltimore) 94(30):e1159CrossRefGoogle Scholar
  64. Okayama D, Minami Y, Kataoka S, Shiga T, Hagiwara N (2015) Thyroid function on admission and outcome in patients hospitalized for acute decompensated heart failure. J Cardiol 66:205–211CrossRefPubMedGoogle Scholar
  65. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D (2008) Thyroid hormone and “cardiac metamorphosis”: potential therapeutic implications. Pharmacol Ther 118:277–294CrossRefPubMedGoogle Scholar
  66. Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G (2005) Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118:132–136CrossRefPubMedGoogle Scholar
  67. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L’Abbate A, Mariotti R, Iervasi G (2008) Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:1351–1358CrossRefPubMedGoogle Scholar
  68. Ruggeri RM, Trimarchi F, Biondi B (2017) L- thyroxine replacement therapy in the frail elderly: a challenge in clinical practice. Eur J Endocrinol 177:R199–R217CrossRefPubMedGoogle Scholar
  69. Shirani J, Barron MM, Pierre-Louis ML, Roberts WC (1993) Congestive heart failure, dilated cardiac ventricles, and sudden death in hyperthyroidism. Am J Cardiol 72:365–368CrossRefPubMedGoogle Scholar
  70. Siu CW, Zhang XH, Yung C, Kung AW, Lau CP, Tse HF (2007) Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab 92:1736–1742CrossRefPubMedGoogle Scholar
  71. Squizzato A, Romualdi E, Buttler HR, Gerdes VE (2007) Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 92:2415–2420CrossRefPubMedGoogle Scholar
  72. Stott DJ, Gussekloo J, Kearney PM, Rodondi N, Westendorp RG, Mooijaart S, Kean S, Quinn TJ, Sattar N, Hendry K, Du Puy R, Den Elzen WP, Poortvliet RK, Smit JW, Jukema JW, Dekkers OM, Blum M, Collet TH, McCarthy V, Hurley C, Byrne S, Browne J, Watt T, Bauer D, Ford I (2017a) Study protocol; thyroid hormone replacement for untreated older adults with subclinical hypothyroidism – a randomised placebo controlled trial (TRUST). BMC Endocr Disord 17:6CrossRefPubMedPubMedCentralGoogle Scholar
  73. Stott DJ, et al (TRUST Study Group) (2017b) Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med.  https://doi.org/10.1056/NEJMoa1603825
  74. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238CrossRefPubMedGoogle Scholar
  75. Triggiani V, Iacoviello M (2013) Thyroid disorders in chronic heart failure: from prognostic set-up to therapeutic management. Endocr Metab Immune Disord Drug Targets 13(1):22–37CrossRefPubMedGoogle Scholar
  76. Triggiani V, Iacoviello M, Monzani F, Puzzovivo A, Guida P, Forleo C, Ciccone MM, Catanzaro R, Tafaro E, Licchelli B, Giagulli VA, Guastamacchia E, Favale S (2012) Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. Endocr Metab Immune Disord Drug Targets 12:86–94CrossRefPubMedGoogle Scholar
  77. Triggiani V, Angelo Giagulli V, De Pergola G, Licchelli B, Guastamacchia E, Iacoviello M (2016) Mechanisms explaining the influence of subclinical hypothyroidism on the onset and progression of chronic heart failure. Endocr Metab Immune Disord Drug Targets 16(1):2–7CrossRefPubMedGoogle Scholar
  78. Turnbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clarck F, Evans JG, Young E, Bird T, Smith PA (1977) The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 7:481–493CrossRefGoogle Scholar
  79. Umpierrez GE, Challapalli S, Patterson C (1995) Congestive heart failure due to reversible cardiomyopathy in patients with hyperthyroidism. Am J Med Sci 310:99–102CrossRefPubMedGoogle Scholar
  80. Van Bilsen M, Chien KR (1993) Growth and hypertrophy of the heart: towards an understanding of cardiac specific and inducible gene expression. Cardiovasc Res 27:1140–1149CrossRefPubMedGoogle Scholar
  81. Van Tuyl M, Blommaart PE, De Boer PA et al (2004) Prenatal exposure to thyroid hormone is necessary for normal postnatal development of murine heart and lungs. Dev Biol 272:104–117CrossRefPubMedGoogle Scholar
  82. Vanderpump MPJ (2005) The epidemiology of thyroid diseases. In: Braverman LE, Utiger RD (eds) Werner and Ingbar’s. The thyroid: a fundamental and clinical Text, vol 9. Lippincott-Raven, Philadelphia, pp 398–406Google Scholar
  83. Vanderpump MPJ, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Evans JG, Hasan DM, Rodgers H, Tunbridge F, Young ET (1995) The incidence of thyroid disorders in the community: a twenty-year-follow-up of the Whickham study. Clin Endocrinol 43:55–68CrossRefGoogle Scholar
  84. Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 98:1312–1322CrossRefGoogle Scholar
  85. Watanabe E, Ohsawa H, Noike H, Okamoto K, Tokuyama A, Kanai M, Mineoka K, Miyashita Y, Kantoh S, Hiruta N et al (1995) Dilated cardiomyopathy associated with hyperthyroidism. Intern Med 34:762–767CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Caterina Rizzo
    • 1
  • Margherita Ilaria Gioia
    • 1
  • Giuseppe Parisi
    • 1
  • Vincenzo Triggiani
    • 2
  • Massimo Iacoviello
    • 3
    Email author
  1. 1.School of CardiologyUniversity of Bari “Aldo Moro”BariItaly
  2. 2.Endocrinology UnitUniversity of Bari “Aldo Moro”BariItaly
  3. 3.Cardiology Unit, Cardiothoracic DepartmentPoliclinic University HospitalBariItaly

Personalised recommendations